Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2019;74(1):135–45.
Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med. 2004;164(11):1227–30.
Lee TH, Kantoff PW, McNaughton-Collins MF. Screening for prostate cancer. N Engl J Med. 2009;360(13): e18.
Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595–605.
Welch HG, Albertsen PC. Reconsidering prostate cancer mortality—the future of PSA screening. N Engl J Med. 2020;382(16):1557–63.
Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening—a perspective on the current state of the evidence. N Engl J Med. 2017;376(13):1285–9.
Gretzer MB. Partin AWJEUS: PSA levels and the probability of prostate cancer on biopsy. Eur Urol Suppl. 2002;1(6):21–7.
Bibbins-Domingo K, Grossman DC, Curry SJ. The US preventive services task force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017;317(19):1949–50.
Nakano Y, Okamura K, Takamura S, Okamoto N. Nagasaka TJIJoU: measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4–20 ng/mL. Int J Urol. 2010;12(8):721–7.
Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: a meta-analysis. Medicine (Baltimore). 2018;97(13):e0249.
Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(1):12–9.
Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174(6):1347–60.
Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404–16.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
Zeng S, Ying Y, Xing N, Wang B, Qian Z, Zhou Z, Zhang Z, Xu W, Wang H, Dai L, et al. Noninvasive detection of urothelial carcinoma by cost-effective low-coverage whole-genome sequencing from urine-exfoliated cell DNA. Clin Cancer Res. 2020;26(21):5646–54.
Feng S, Ding Z, Wang J, Qian Z, Li S, Zhang C, Xin H, Liu S, Ding G, Hu M, et al. Investigation of plasma cell-free cancer genome chromosomal instability as a tool for targeted minimally invasive biomarkers for primary liver cancer diagnoses. Cancer Med. 2020;9(14):5075–85.
Zhou H, Wang XJ, Jiang X, Qian Z, Chen T, Hu Y, Chen ZH, Gao Y, Wang R, Ye WW, et al. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse. Breast Cancer Res Treat. 2019;178(1):63–73.
Wang X, Fu XH, Qian ZL, Zhao T, Duan AQ, Ruan X, Zhu B, Yin L, Zhang YJ, Yu WL. Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: a prospective cohort study. Transl Oncol. 2021;14(1):100908.
Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.
Wang X, Grasso CS, Jordahl KM, Kolb S, Nyame YA, Wright JL, Ostrander EA, Troyer DA, Lance R, Feng Z, et al. Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(3):494–506.
Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci USA. 2019;116(23):11390–5.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. Genome project data processing S: the sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
Seshan VE, Olshen A. DNAcopy: DNA copy number data analysis. R package version 1530. 2017.
Guo J, Yang J, Zhang X, Feng X, Zhang H, Chen L, Johnson H, Persson JL, Xiao K. A panel of biomarkers for diagnosis of prostate cancer using urine samples. Anticancer Res. 2018;38(3):1471–7.
Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894–904.
Kotwal AA, Schumm P, Mohile SG, Dale W. The influence of stress, depression, and anxiety on PSA screening rates in a nationally representative sample. Med Care. 2012;50(12):1037–44.
Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. Urology. 2003;61(4):760–4.
Kuznetsova AY, Seget K, Moeller GK, de Pagter MS, de Roos JA, Durrbaum M, Kuffer C, Muller S, Zaman GJ, Kloosterman WP, et al. Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells. Cell Cycle. 2015;14(17):2810–20.
Bakhoum SF, Landau DA. Chromosomal instability as a driver of tumor heterogeneity and evolution. Cold Spring Harb Perspect Med. 2017;7(6):a029611.
Choyke PL, Loeb S. Active surveillance of prostate cancer. Oncology (Williston Park). 2017;31(1):67–70.
Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–33.
Russo G, Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Giordano A, Autran-Gomez A, Di Monaco F, Di Silverio F, Sale P, et al. p53 gene mutational rate, Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation? J Med Virol. 2008;80(12):2100–7.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.